Browse by Poster Presenter

Type here to filter the list

A
Abdelhady, Ahmed

Intellia Therapeutics
PI-087 - POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSIS FOR NTLA-2002 IN PATIENTS WITH HEREDITARY ANGIOEDEMA
Ahmed Abdelhady
Favorite
Abor, Evans

University of Cincinnati
PII-027 - CHARACTERIZING NETUPITANT'S FUNCTION AS AN NADK2 INHIBITOR: IMPACT ON CELL VIABILITY AND METABOLISM.
Evans Abor
Favorite
Abou Warda, Ahmed

October 6 University
LB-007 - GENETIC POLYMORPHISMS IN SLC5A2 ARE ASSOCIATED WITH CLINICAL OUTCOMES AND SGLT2I RESPONSE IN HEART FAILURE PATIENTS.
Ahmed Abou Warda
Favorite
Abulfathi, Ahmed

Certara USA
PI-017 - CONCENTRATION-RESPONSE RELATIONSHIP OF MAM01, AN INVESTIGATIONAL MONOCLONAL ANTIBODY TARGETING THE CIRCUMSPOROZOITE PROTEIN (CSP), IN A CONTROLLED HUMAN INFECTION MODEL (CHIM) STUDY.
Ahmed Abulfathi
Favorite
Adhikari, Saugat

Pfizer Inc
PI-054 - A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL DESIGN, STUDY TO EVALUATE PHARMACOKINETIC COMPARABILITY OF TWO PF-07940367 FILM-COATED TABLET FORMULATIONS ADMINISTERED AS 150 MG UNDER FASTED CONDITIONS IN HEALTHY PARTICIPANTS
Saugat Adhikari
Favorite
Ajavon-Hartmann, Antoinette

Bristol Myers Squibb
PII-071 - INTEGRATED MODEL BASED ANALYSES OF MILVEXIAN PHASE 2 SSP TRIAL DATA SUPPORTS PHASE 3 DOSE SELECTION
Antoinette Ajavon-Hartmann
Favorite
Al Sahlawi, Sulafa

Univeristy of Florida
LB-020 - DEVELOPMENT OF AN R SHINY APPLICATION TO STREAMLINE DRUG-DRUG INTERACTION SIMULATIONS UTILIZING THE SIMCYP-R PACKAGE.
Sulafa Al Sahlawi
Favorite
Al Yacoub, Omar

AbbVie
PI-121 - OPTIMIZING THE FIRST-IN-HUMAN STUDY DESIGN FOR BIOLOGICS EXHIBITING TARGET-MEDIATED DRUG DISPOSITION
Omar Al Yacoub
Favorite
AlAzzeh, Ola

Virginia Commonwealth University School of Pharmacy
PII-048 - GENOME-WIDE ASSOCIATION STUDY OF CENTRAL NERVOUS SYSTEM MEDICATION-INDUCED ADVERSE DRUG REACTIONS AMONG A SUBSET OF PARTICIPANTS IN THE NIH ALL OF US RESEARCH PROGRAM
Ola AlAzzeh
Favorite
Aldhafiri, Wafaa

AstraZeneca
PT-023 - DEVELOPMENT OF AN ADVANCED PBPK MODEL OF THE RESPIRATORY TRACT TO OPTIMIZE PULMONARY DELIVERY AND DOSING OF MO-OH-NAP TROPOLONE NANO-FORMULATION.
Wafaa Aldhafiri
Favorite
Alhurayri, Fatimah

Purdue University
PT-006 - PHARMACOKINETIC DRUG-DRUG INTERACTION POTENTIAL OF ORAL ANTICANCER DRUGS.
Fatimah Alhurayri
Favorite
Almond, Lisa

Certara UK
PI-113 - PBPK-LED ASSESSMENT OF ANTIMALARIAL DRUG CONCENTRATIONS IN BREASTMILK: A STRATEGY FOR OPTIMAL USE OF PREDICTION METHODS TO GUIDE DECISION MAKING IN AN UNDERSTUDIED POPULATION
Lisa Almond
Favorite
Alqurashi, Roaya

Umm Al-Qura University | Maternity & Children’s Hospital
PI-009 - ASSESSMENT OF KNOWLEDGE AND PERCEPTION OF CAR-T CELL THERAPY AMONG HEALTHCARE PROVIDERS IN SAUDI ARABIA
Roaya Alqurashi
Favorite
PII-009 - EVALUATION OF ANTIBIOTIC TREATMENTS FOR CELLULITIS: A SYSTEMATIC REVIEW FROM CLINICALTRIALS.GOV
Roaya Alqurashi
Favorite
Alshahawey, Mona

Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida
PI-046 - GENOME WIDE ASSOCIATION STUDY OF APPARENT TREATMENT RESISTANT HYPERTENSION (ATRH): INSIGHTS FROM THE ALL OF US RESEARCH PROGRAM.
Mona Alshahawey
Favorite
Alshammari, Raed

University of Florida
PII-051 - METHYLATION PROFILING AND PATHWAY ENRICHMENT ANALYSIS REVEAL EPIGENETIC MECHANISMS IN CARFILZOMIB-RELATED CARDIOTOXICITY IN MULTIPLE MYELOMA PATIENTS .
Raed Alshammari
Favorite
Ardeshiri, Ardalan

Boundless Bio
PI-126 - APPLICATION OF MACHINE LEARNING TO GUIDE OPTIMAL FORMULATION SELECTION IN EARLY-STAGE DRUG DISCOVERY
Ardalan Ardeshiri
Favorite
Ayalasomayajula, Surya

MRL-TMED-QP2
PII-059 - ASSESSMET OF SUBCUTANEOUS SITE OF INJECTION ON THE PK OF SOTATERCEPT
Surya Ayalasomayajula
Favorite
B
Babatunde, Olajumoke

Virginia Commonwealth University
LB-009 - LEVERAGING CPIC LEVEL 1A PHARMACOGENOMICS INSIGHTS TO MITIGATE ADVERSE DRUG EVENTS IN OLDER ADULTS: EVIDENCE FROM VIRGINIA ALL-PAYER CLAIMS DATABASE 2016-2020.
Olajumoke Babatunde
Favorite
Bargal, Salma

University of Maryland School of Medicine
PT-009 - SHORT-TERM PHARMACODYNAMIC EFFECTS OF CANAGLIFLOZIN IN HEALTHY AMISH VOLUNTEERS
Salma Bargal
Favorite
PWI-002 - SHORT-TERM PHARMACODYNAMIC EFFECTS OF CANAGLIFLOZIN IN HEALTHY AMISH VOLUNTEERS
Salma Bargal
Favorite
Bartlette, Kai

Allucent
PII-076 - MODEL-ESTIMATED TISSUE PHARMACOLOGY AS A SURROGATE OF MONOCLONAL ANTIBODY CLINICAL EFFICACY DOSE RESPONSE: CASE STUDY USING DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS.
Kai Bartlette
Favorite
Beaudoin, James

QSP Solutions, Simulations Plus Inc.
PII-125 - QUANTITATIVE SYSTEMS TOXICOLOGY (QST) MODELING USING BIOLOGXSYM AND MECHANISTIC TOXICITY DATA FROM A BIOMIMETIC LIVER MICROPHYSIOLOGY SYSTEM PREDICTS BIOLOGICS-INDUCED LIVER INJURY (BILI) FOR MULTIPLE LARGE MOLECULES.
James Beaudoin
Favorite
Bedathuru, Dinesh

VANTAGE RESEARCH INC
E-004 - DEVELOPMENT OF QSP PLATFORM MODEL FOR PREDICTING CLINICAL EFFICACY AND CRS INCIDENCE OF CD3 BISPECIFICS IN STEAP1 PROSTATE CANCER
Dinesh Bedathuru
Favorite
Bergagnini-Kolev, Mackenzie

Simcyp/Certara
PI-098 - PBPK MODEL REPRODUCIBILITY: LEARNINGS FROM THE DEVELOPMENT OF A PBPK MODEL REPOSITORY FOR GLOBAL HEALTH
Mackenzie Bergagnini-Kolev
Favorite
Bergeron, Maxime

InsightRX
PI-071 - LEVERAGING AGENTIC WORKFLOWS FOR PK/PD ANALYSIS: ENHANCING CLINICAL PHARMACOLOGY DECISION-MAKING
Maxime Bergeron
Favorite
Bertz, Richard

Biohaven
LB-021 - TRANSLATION OF RAT TO HUMAN BRAIN CONCENTRATIONS USING PBPK MODELING CONFIRMS HIGH BRAIN PENETRATION OF THE TYK2/JAK1 INHIBITOR BHV-8000.
Richard Bertz
Favorite
Bhattacharya, Chandrali

Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca
TIP-001 - DIVERSITY IN ACTION, CASE STUDIES OF ASTRAZENECA-SPONSORED PHASE-I TRIALS.
Chandrali Bhattacharya
Favorite
Binte Islam, Nabhira Aftabi

Bangabandhu Sheikh Mujib Medical University (bsmmu)
PII-010 - PHYSICIAN PERCEPTIONS ON ORAL HEALTH FOR PREGNANT WOMEN: BANGLADESH PERSPECTIVE
Nabhira Aftabi Binte Islam
Favorite
Block, Michael

Bayer AG
PI-124 - AN INTEGRATED ANALYSIS OF FOUR TARGETED THORIUM CONJUGATES TO ASSESS THE TH-227 AND RA-223 DISTRIBUTION AND TISSUE-RELATED RADIATION.
Michael Block
Favorite
Boelig, Rupsa

Sidney Kimmel Medical College, Thomas Jefferson University
PII-024 - CHARACTERIZING METHADONE:METABOLITE RATIO DURING METHADONE INDUCTION IN PREGNANCY
Rupsa Boelig
Favorite
Brennan, Barbara

Bayer
PI-012 - CONCENTRATION-QT ANALYSIS FOR BAY 2927088 INDICATES NO CLINICALLY RELEVANT QTC INTERVAL PROLONGATION
Barbara Brennan
Favorite
PI-065 - EFFECT OF FOOD AND ESOMEPRAZOLE ON THE PHARMACOKINETICS (PK) OF BAY 2927088
Barbara Brennan
Favorite
PII-022 - CLINICAL DRUG-DRUG INTERACTION STUDIES INVESTIGATING THE EFFECT OF BAY 2927088 ON P-GP AND BCRP USING DABIGATRAN ETEXILATE AND ROSUVASTATIN
Barbara Brennan
Favorite
PII-061 - CLINICAL DRUG-DRUG INTERACTION STUDIES THROUGH CYTOCHROME P450 3A (CYP3A) AND P-GLYCOPROTEIN (P-GP) FOR BAY 2927088 USING ITRACONAZOLE (ITZ), CARBAMAZEPINE (CBZ) AND MIDAZOLAM (MDZ)
Barbara Brennan
Favorite
Brstilo, Lucas

Hospital de Pediatría JP Garrahan
LB-014 - POPULATION PHARMACOKINETICS AND BIOAVAILABILITY OF TACROLIMUS ORAL SUSPENSION IN CHILDREN WITH HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
Lucas Brstilo
Favorite
Burckart, Gilbert

US Food and Drug Administration
PI-111 - DEVELOPMENT OF A QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL TO CHARACTERIZE THE EFFECTS OF INHALED CORTICOSTEROIDS ON PEDIATRIC BONE HEALTH.
Gilbert Burckart
Favorite
Burger, David

Radboud University Medical Center
PI-064 - DRUG-DRUG INTERACTIONS BETWEEN ANDROGEN RECEPTOR SIGNALING INHIBITORS AND DIRECT-ACTING ORAL ANTICOAGULANTS IN PATIENTS WITH PROSTATE CANCER: LIMITED AGREEMENT BETWEEN VARIOUS DRUG-DRUG INTERACTION INFORMATION SOURCES
David Burger
Favorite
PII-065 - DRUG-DRUG INTERACTIONS BETWEEN LETERMOVIR AND TARGETED THERAPIES FOR GRAFT VERSUS HOST DISEASE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: HOW DO DRUG-DRUG INTERACTION CHECKERS COMPARE?
David Burger
Favorite
Burnett, Joseph

Bristol Myers Squibb
PII-040 - THE IMPACT OF MILD, MODERATE AND SEVERE LIVER DYSFUNCTION ON THE PHARMACOKINETIC DISPOSITION OF MEZIGDOMIDE
Joseph Burnett
Favorite
Burns, Anna

Children's Mercy Kansas City
PII-127 - MEETING CLINICAL TRIAL RECRUITMENT MILESTONES IN ACADEMIC CENTERS: A DATA-DRIVEN VISUAL APPROACH
Anna Burns
Favorite
Bustion, Annamarie

University of California San Francisco
PII-094 - UNRAVELING MOXIFLOXACIN'S BEHAVIOR IN NEXT-GENERATION TB REGIMENS.
Annamarie Bustion
Favorite
C
Cao, Brad

UMB
PII-072 - LEVERAGING SUPERVISED MACHINE LEARNING TO IDENTIFY PREDICTORS OF ADVERSE EVENTS WITH STIMULANT TREATMENT FROM REAL-WORLD DATA
Brad Cao
Favorite
Chaba, Linda

UCSF
PI-006 - OPTIMIZING REGIMEN COMBINATIONS FOR TUBERCULOSIS DRUG DEVELOPMENT.
Linda Chaba
Favorite
Chan, Rosa

Longboard Pharmaceuticals
PI-063 - DISPOSITION OF BEXICASERIN TO ITS MAJOR METABOLITE, N-CARBAMOYL GLUCURONIDE (M20), IS NOT INFLUENCED BY GENETIC POLYMORPHIC METABOLISM
Rosa Chan
Favorite
Chen Gan, Jia Wen

UC San Diego
PII-119 - EVALUATING AND OPTIMIZING ALLOMETRIC SCALING APPROACHES FOR PREDICTING PEDIATRIC EXPOSURES OF INTRAVENOUSLY ADMINISTERED SMALL MOLECULES AND BIOLOGICS FROM ADULT DATA
Jia Wen Chen Gan
Favorite
Chenchula, Santenna

ALL INDIA INSTITUTE OF MEDICAL SCIENCES, Bhopal
PI-045 - FREQUENCIES OF CLINICALLY ACTIONABLE POLYMORPHISMS, GENOTYPES, AND PHENOTYPES OF CYP2D6 AND CYP2C19 GENES IN THE CENTRAL INDIAN POPULATION WITH COMMON MENTAL DISORDERS
Santenna Chenchula
Favorite
Cheng, Limei

Incyte Corporation
PII-053 - A NOVEL MODELING APPROACH FOR PREDICTING THE TIME COURSE OF ANTI-DRUG ANTIBODIES OF BIOLOGICS: APPLICATION TO AXATILIMAB AS AN EXAMPLE
Limei Cheng
Favorite
Cheng, Lucy

Emory College
PII-069 - EXTERNAL EVALUATION OF A POPULATION PHARMACOKINETICS MODEL OF CRITICALLY ILL PEDIATRIC PATIENTS RECEIVING MEROPENEM
Lucy Cheng
Favorite
Cheng, Yi-Hsien

U.S. Food and Drug Administration
PII-095 - ASSESSMENT OF THE IMPACT OF NON-COMPARABLE IN VITRO ALCOHOL DOSE DUMPING RELEASE ON SYSTEMIC EXPOSURE USING PBPK ABSORPTION MODELING FOR TOPIRAMATE EXTENDED-RELEASE CAPSULES.
Yi-Hsien Cheng
Favorite
Chen, Yang

Daiichi Sankyo
PI-030 - EFFECT OF VALEMETOSTAT ON THE PHARMACOKINETICS OF MIDAZOLAM AND DIGOXIN (CYP3A AND P-GP SUBSTRATES): A PHASE 1 DRUG-DRUG INTERACTION STUDY IN PATIENTS WITH REFRACTORY OR RELAPSED NON-HODGKIN LYMPHOMA.
Yang Chen
Favorite
Chen, Ying-Jung

Department of Pharmacy, National Taiwan University Hospital
LB-019 - CAN PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING COMPLEMENT THERAPEUTIC DRUG MONITORING FOR DIGOXIN DOSE OPTIMIZATION IN PATIENTS WITH RENAL IMPAIRMENT?
Ying-Jung Chen
Favorite
Chen, Yingxue

Ipsen
PI-078 - PHARMACOKINETIC INTERACTION STUDIES OF COADMINISTRATION OF TAZEMETOSTAT WITH FLUCONAZOLE, REPAGLINIDE, OR OMEPRAZOLE IN PATIENTS WITH ADVANCED MALIGNANCIES.
Yingxue Chen
Favorite
Chen, Yizhe

Bristol Myers Squibb
PII-067 - EXPOSURE RESPONSE (E-R) RELATIONSHIPS OF FEDRATINIB IN PATIENTS WITH INTERMEDIATE-2 TO HIGH-RISK MYELOFIBROSIS WITH OR WITHOUT PRIOR RUXOLITNIB EXPOSURE.
Yizhe Chen
Favorite
Cho, Yong-Soon

Center for Personalized Precision Medicine of Tuberculosis, Inje University College of Medicine
PII-062 - COMPREHENSIVE PHARMACOKINETIC ANALYSIS OF ISONIAZID IN A LARGE COHORT OF TUBERCULOSIS PATIENTS: ADVANCED MODELING INCORPORATING EXTENSIVE CLINICAL COVARIATES.
Yong-Soon Cho
Favorite
Cho, Youngwoo

UChicago Medicine
OAI-001 - YOURPGX ONCOLOGY: A NOVEL DIRECT-TO-PATIENT PORTAL FOR DELIVERING PHARMACOGENOMIC (PGX) RESULTS
Youngwoo Cho
Favorite
PT-010 - YOURPGX ONCOLOGY: A NOVEL DIRECT-TO-PATIENT PORTAL FOR DELIVERING PHARMACOGENOMIC (PGX) RESULTS
Youngwoo Cho
Favorite
Chung, Taekyu

University of California San Francisco
PI-056 - ALTERNATIVE DOSING GUIDELINES TO IMPROVE OUTCOMES IN MULTIDRUG-RESISTANT TUBERCULOSIS.
Taekyu Chung
Favorite
Collins, Keagan

Pfizer
PII-036 - PRECLINICAL TO CLINICAL TRANSLATION OF ADVERSE EVENTS FOR SMALL MOLECULE ONCOLOGY DRUGS
Keagan Collins
Favorite
PII-038 - STRATEGIC CONSIDERATIONS FOR TUMOR DYNAMICS MODELING IN EARLY DEVELOPMENT: LEARNINGS FROM AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE
Keagan Collins
Favorite
D
de Castro Suarez, Niurys

UCSF
PI-092 - THE SUPER APPROACH AS AN ALTERNATIVE FOR ESTIMATING THE PKPD PARAMETERS OF DRUGS IN COMBINATION THERAPIES
Niurys de Castro Suarez
Favorite
Deferm, Neel

Certara
PI-094 - ANALYZING AND INTEGRATING POSTPARTUM PHYSIOLOGICAL CHANGES IN LACTATING WOMEN.
Neel Deferm
Favorite
Dehn, Clayton

Evolution Research Group
PII-006 - PHARMACODYNAMIC MODELS AS EARLY PREDICTORS OF WEIGHT LOSS EFFICACY IN EARLY-PHASE CLINICAL RESEARCH
Clayton Dehn
Favorite
Delaney, Karina

Mayo Clinic
PII-025 - THE POTENTIAL OF SMARTWATCH-DERIVED CARDIAC MEASUREMENTS AS BIOMARKERS OF THERAPEUTIC RESPONSE IN CHILDREN WITH DISRUPTIVE BEHAVIOR DISORDER
Karina Delaney
Favorite
Dibbets, Anna Caroline

Department of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands
PI-104 - BARRIERS AND FACILITATORS IN BRINGING MODEL-INFORMED PRECISION DOSING TO THE PATIENT'S BEDSIDE: A SYSTEMATIC REVIEW
Anna Caroline Dibbets
Favorite
PII-111 - ESTABLISHING EVIDENCE-BASED, ANTENATAL DOSE RECOMMENDATIONS FOR AMOXICILLIN (WITH AND WITHOUT CLAVULANIC ACID)
Anna Caroline Dibbets
Favorite
Diep, John

Ionis
PII-087 - POPULATION PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MODELING OF DONIDALORSEN, AN ANTISENSE OLIGONUCLEOTIDE IN DEVELOPMENT FOR PROPHYLAXIS OF HEREDITARY ANGIOEDEMA.
John Diep
Favorite
Ding, Jing

Psychotherapy Research and Development Program, VA NY Harbor Healthcare System
LB-006 - CLINICAL AND ETHICAL PERSPECTIVES ON THE EMERGING ROLE OF PHARMACOGENOMIC TESTING AMONG MENTAL HEALTH PROVIDERS: A QUALITATIVE EXAMINATION
Jing Ding
Favorite
Dinh, Jean

Certara UK
LB-018 - BUILDING AN OAT-MATRIX: PERFORMANCE VERIFICATION OF IVIVE-PBPK MODELS IN THE PREDICTION OF OAT1/OAT3 MEDIATED DRUG-DRUG INTERACTIONS
Jean Dinh
Favorite
PI-095 - BUILDING AN OATP1B-MATRIX: PERFORMANCE VERIFICATION OF IVIVE-PBPK MODELS IN THE PREDICTION OF OATP1B1/1B3 MEDIATED DRUG-DRUG INTERACTIONS
Jean Dinh
Favorite
DJEBLI, Nassim

Luzsana / Hengrui
PI-066 - EXPLORATORY POPULATION PHARMACOKINETICS AND WEIGHT LOSS MODELING OF HRS9531, A NOVEL DUAL GLP-1/GIP RECEPTOR AGONIST IN CHINESE OBESE ADULTS
Nassim DJEBLI
Favorite
PI-067 - EXPOSURE-EFFICACY ANALYSIS OF CAMRELIZUMAB PLUS RIVOCERANIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA.
Nassim DJEBLI
Favorite
PII-001 - POPULATION PHARMACOKINETICS OF TRASTUZUMAB REZETECAN IN PATIENTS WITH HER2 EXPRESSING OR MUTATED ADVANCED MALIGNANT SOLID TUMORS
Nassim DJEBLI
Favorite
PII-086 - POPULATION PHARMACOKINETIC MODELING OF FAMITINIB IN PATIENTS WITH VARIOUS CANCER TYPES INCLUDING METASTATIC CERVICAL CANCER
Nassim DJEBLI
Favorite
PII-088 - POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSIS FOR THE BIFUNCTIONAL PD-L1/TGF-βRII FUSION PROTEIN RETLIRAFUSP ALPHA TO SUPPORT A FLAT DOSE AS AN ALTERNATIVE REGIMEN
Nassim DJEBLI
Favorite
PII-100 - PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELLING FOR PREDICTING DRUG-DRUG INTERACTIONS (DDI) OF SHR2554
Nassim DJEBLI
Favorite
Dodeja, Prerna

University of Pittsburgh School of Pharmacy
PI-114 - POPULATION PHARMACOKINETIC ANALYSIS TO OPTIMIZE THE DOSING REGIMEN OF 17-OHPC FOR PREVENTION OF PRETERM BIRTH
Prerna Dodeja
Favorite
Dogterom, Peter

QPS Netherlands
PI-014 - RESULTS OF A PHASE 1 CLINICAL TRIAL (GH001-HV-103) TO DETERMINE THE SAFETY AND TOLERABILITY OF MEBUFOTENIN (5-MEO-DMT), ADMINISTERED VIA INHALATION (GH001) IN HEALTHY SUBJECTS.
Peter Dogterom
Favorite
PII-081 - PHARMACOKINETICS OF THB001, AN ORALLY AVAILABLE, POTENT AND HIGHLY SELECTIVE SMALL MOLECULE INHIBITOR OF WILD TYPE KIT RECEPTOR TYROSINE KINASE, IN HEALTHY VOLUNTEERS
Peter Dogterom
Favorite
Dong, Jin

AstraZeneca
PII-109 - A LITERATURE REVIEW OF DRUG-DRUG-DISEASE INTERACTION IN PATIENTS WITH HEPATIC OR RENAL IMPAIRMENT.
Jin Dong
Favorite
Drescher, Stefanie

Pfizer, Inc.
PI-108 - BALANCING BROADENED ELIGIBILITY CRITERIA AND NECESSARY RESTRICTIONS IN ONCOLOGY CLINICAL STUDIES FOR ORGAN IMPAIRMENT
Stefanie Drescher
Favorite
E
East, Lilly

Sarepta Therapeutics, Inc.
PII-075 - MODEL-BASED EVALUATION OF DELANDISTROGENE MOXEPARVOVEC ADENO-ASSOCIATED VIRUS PHARMACOKINETICS AND SAFETY IMPLICATIONS
Lilly East
Favorite
Elmokadem, Ahmed

Metrum Research Group
PI-081 - PHARMACOMETRIC MACHINE LEARNING: INTEGRATING NEURAL NETWORKS FOR FLEXIBLE, ADVANCED COVARIATE ANALYSIS
Ahmed Elmokadem
Favorite
Elsayed, Abdelrahman

St. Jude Children's Research Hospital
OAI-004 - GRIN2 IS A POWERFUL TOOL TO IDENTIFY GENOMIC HOT-SPOT LOCI AND ENABLES MULTI-OMICS INTEGRATION.
Abdelrahman Elsayed
Favorite
PT-005 - GRIN2 IS A POWERFUL TOOL TO IDENTIFY GENOMIC HOT-SPOT LOCI AND ENABLES MULTI-OMICS INTEGRATION.
Abdelrahman Elsayed
Favorite
Elzein, Rola

School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, USA
PI-119 - EUGLYCEMIC CLAMP STUDY DESIGNS FOR NOVEL INSULINS AND INSULIN BIOSIMILARS.
Rola Elzein
Favorite
Etkins, Jumar

Indiana University School of Medicine
LB-008 - GENOTYPE-SPECIFIC SAFTEY PROFILES AND PHARMACOKINETICS OF CANNABIDIOL IN HEALTHY SUBJECTS
Jumar Etkins
Favorite
Ette, Mfonabasi

University at Buffalo
LB-010 - A PHARMACOLOGY AND PHYSIOLOGY ENABLED MACHINE LEARNING MODEL FOR PHARMACOKINETICS OF ANTIBODY-BASED THERAPEUTICS
Mfonabasi Ette
Favorite
F
Flohr, Rylie

University of Florida
LB-007 - GENETIC POLYMORPHISMS IN SLC5A2 ARE ASSOCIATED WITH CLINICAL OUTCOMES AND SGLT2I RESPONSE IN HEART FAILURE PATIENTS.
Rylie Flohr
Favorite
PII-047 - GENOME-WIDE ASSOCIATION STUDY IDENTIFIES ASSOCIATIONS WITH METHOTREXATE RESPONSE IN PULMONARY SARCOIDOSIS.
Rylie Flohr
Favorite
Flynn, Courtney

Indivior
PI-025 - PATIENT PROFILES OF OPIOID USE DISORDER PATIENTS TREATED WITH ORAL VERSUS MONTHLY INJECTABLE BUPRENORPHINE USING U.S. REAL-WORLD MEDICAID CLAIMS DATA.
Courtney Flynn
Favorite
Fofanova, Irina

University of Florida
TIP-002 - EVALUATION OF A PHARMACIST-LED PHARMACOGENETICS CONSULTATION SERVICE ON HEALTHCARE COSTS AND OUTCOMES.
Irina Fofanova
Favorite
G
Garhyan, Arnay

Park Tudor High School
PI-117 - DEVELOPMENT OF POPULATION PHARMACOKINETICS MODEL AND R-SHINY SIMULATION PLATFORM FOR MOXIFLOXACIN IN NON-HUMAN PRIMATES
Arnay Garhyan
Favorite
Gastonguay, Marc

Metrum Research Group
PII-063 - COST EFFECTIVENESS OF INDIVIDUALIZED DOSING FOR A HYPOTHETICAL NEW DRUG IN ATOPIC DERMATITIS: A PHARMACOMETRIC-PHARMACOECONOMIC SIMULATION STUDY.
Marc Gastonguay
Favorite
Gawronski, Brian

University of Florida
LB-007 - GENETIC POLYMORPHISMS IN SLC5A2 ARE ASSOCIATED WITH CLINICAL OUTCOMES AND SGLT2I RESPONSE IN HEART FAILURE PATIENTS.
Brian Gawronski
Favorite
PII-044 - DEMOGRAPHICS AND UTILIZATION OF MEDICATIONS WITH PHARMACOGENETICS GUIDELINES IN THE TRIAL OF PREMPTIVE PHARMAGOGENETICS IN UNDERSERVED PATIENTS (TOPP UP)
Brian Gawronski
Favorite
Gershuny, Victoria

U.S. Food and Drug Administration
PII-107 - CLINICAL STUDY TO INVESTIGATE THE EFFECT OF ADMINISTRATION OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS AND AN OPIOID ON VENTILATION.
Victoria Gershuny
Favorite
Ghasemi, Mohammad

Arcus Biosciences
PI-059 - CASDATIFAN (AB521) PHARMACOKINETICS IS SIMILAR WHEN ADMINISTERED AS CAPSULES OR TABLETS AND IS UNAFFECTED BY FOOD
Mohammad Ghasemi
Favorite
Gillis, Nancy

Moffitt Cancer Center and Research Institute
PII-028 - CLONAL HEMATOPOIESIS AS A PRECISION MEDICINE BIOMARKER FOR PATIENTS WITH CANCER
Nancy Gillis
Favorite
Gong, Xiaohua

Incyte Corporation
PI-029 - EFFECT OF HEPATIC FUNCTION IMPAIRMENT ON THE PHARMACOKINETICS (PK) OF PARSACLISIB, A SELECTIVE INHIBITOR OF PI3Kδ
Xiaohua Gong
Favorite
PII-029 - EFFECT OF RENAL FUNCTION IMPAIRMENT ON THE PHARMACOKINETICS (PK) OF PARSACLISIB, A SELECTIVE INHIBITOR OF PI3Kδ
Xiaohua Gong
Favorite
Gooden, Felicia

University of Cincinnati/Cincinnati Children's Hospital Medical Center
PI-048 - GREATER METHOTREXATE EXPOSURE IN HSLCO1B1*14 TRANSGENIC MICE AS THE RESULT OF PHARMACOGENOMIC GUIDED-DOSING NORMALIZES THERAPEUTIC RESPONSE
Felicia Gooden
Favorite
Goti, Vineet

Bristol Myers Squibb
PI-072 - LIKELY INHIBITION OF NON-CYP450 PATHWAYS BY BMS-986196 LEADS TO DOUBLING OF EE EXPOSURE.
Vineet Goti
Favorite
Grant, Caroline

Mayo Clinic
OAII-002 - EXTREME GRADIENT BOOSTING COMPARED TO TRADITIONAL MODELING FOR PREDICTING PROGRESSION-FREE AND OVERALL SURVIVAL IN PATIENTS WITH RENAL CELL CARCINOMA
Caroline Grant
Favorite
PI-075 - MODEL-BASED META-ANALYSIS OF PLACEBO-RESPONSE FOR MONTHLY MIGRAINE DAYS IN MIGRAINE PREVENTION CLINICAL TRIALS FROM LITERATURE
Caroline Grant
Favorite
PT-003 - EXTREME GRADIENT BOOSTING COMPARED TO TRADITIONAL MODELING FOR PREDICTING PROGRESSION-FREE AND OVERALL SURVIVAL IN PATIENTS WITH RENAL CELL CARCINOMA
Caroline Grant
Favorite
Gronich, Naomi

Faculty of Medicine - Technion - Israel Institute of Technology; Clalit Health Services
E-001 - MEDICATIONS AND ACUTE HEMOLYSIS IN G6PD-DEFICIENT PATIENTS A REAL-WORLD STUDY. Received February 25, 2024; accepted May 20, 2024. doi:10.1002/cpt.3333
Naomi Gronich
Favorite
LB-002 - ASSOCIATION BETWEEN TREATMENT FOR MULTIPLE SCLEROSIS IN PREGNANCY AND PRECONCPETION PERIODS AND FETAL OUTCOMES - A REAL-WORLD RETROSPECTIVE COHORT STUDY
Naomi Gronich
Favorite
Guo, Cen Cathy

Pfizer
LB-005 - TALAZOPARIB FORMULATION BRIDGING IN CANCER PATIENTS-CHALLENGES AND THE CRITICAL ROLE OF MIDD IN APPROVAL DESPITE FAILED BIOEQUIVALENCE
Cen Cathy Guo
Favorite
Guttendorf, Robert

Aclairo Pharmaceutical Development Group, Inc.
PI-106 - SAFETY AND PHARMACOKINETICS OF DF-003, A TARGETED, FIRST-IN-CLASS ALPHA-KINASE 1 INHIBITOR FOR TREATMENT OF THE RARE GENETIC DISEASE, ROSAH SYNDROME.
Robert Guttendorf
Favorite
H
Halsey, Trey

Virginia Commonwealth University School of Pharmacy
PI-018 - INTERPLAY BETWEEN HIV AND METHADONE: EFFECTS ON CHEMOKINE DYSREGULATION AND NEUROINFLAMMATION.
Trey Halsey
Favorite
Haque, Abid

Quantitative Pharmacology & Pharmacometrics, Translational Medicine, Merck & Co., Inc., Rahway, NJ, USA
PI-096 - LEVERAGING PBPK MODELING TO ENHANCE THE TRANSLATABILITY OF HALF-LIFE EXTENDED MONOCLONAL ANTIBODIES
Abid Haque
Favorite
Hartauer, Mattie

University of North Carolina Chapel Hill
PI-023 - INCORPORATING HEPATIC TRANSPORTER ZONATION INTO PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELS: IMPLICATIONS FOR PRAVASTATIN DISPOSITION IN WHITE AND CHINESE POPULATIONS CONSIDERING OATP1B1 PHENOTYPES.
Mattie Hartauer
Favorite
Hasan, Khaled

School of Pharmacy and Health Professions, University of Maryland Eastern Shore
PII-123 - A STUDY ON THE PREVALENCE OF CHRONIC CANNABINOID USE INDUCING HYPEREMESIS SYNDROME
Khaled Hasan
Favorite
Heruye, Segewkal Hawaze

Indiana University
LB-001 - MODELING AND SIMULATION OF POLYAMINE KINETICS DURING ACUTE KIDNEY INJURY
Segewkal Hawaze Heruye
Favorite
Hess, Kaitlyn

UCHealth
PII-052 - PRECISION MEDICINE IN PRACTICE: DEVELOPMENT OF AN AUTOMATED WARFARIN PHARMACOGENOMIC DOSING CALCULATOR EMBEDDED IN THE ELECTRONIC HEALTH RECORD.
Kaitlyn Hess
Favorite
Ho, Brian

University at Buffalo
PT-011 - DEVELOPING A SIMULTANEOUS PLASMA AND CENTRAL NERVOUS SYSTEM POPULATION PHARMACOKINETIC MODEL FOR DOLUTEGRAVIR EXPOSURE
Brian Ho
Favorite
Hossain, Nayeem

U.S. Food and Drug Administration
PI-008 - USING BIOMARKERS TO PROVIDE EVIDENCE OF EFFECTIVENESS IN DRUG DEVELOPMENT FOR RARE DISEASES: SURVEY RESULTS FOR APPROVED ENZYME REPLACEMENT THERAPIES.
Nayeem Hossain
Favorite
Ho, Yunn-Fang

National Taiwan University College of Medicine
PII-098 - ON TRANSLATING PHYSIOLOGICALLY BASED PHARMACOKINETICS INTO CLINICAL CARE: REAL-WORLD PREDICTABILITY OF VALPROATE THERAPEUTIC DRUG MONITORING.
Yunn-Fang Ho
Favorite
Huang, Peirung

Purdue University
PI-001 - A LANDSCAPE SURVEY FOR THE PRESENTATIONS APPROVED FOR SUBCUTANEOUS PROTEIN PRODUCTS.
Peirung Huang
Favorite
Huang, Xiaoying

Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego
OAII-004 - UTILIZING ADAPTIVE DOSING SIMULATIONS AND MACHINE LEARNING TO IMPROVE PREDICTION AND MANAGEMENT OF NEUTROPENIA RATES.
Xiaoying Huang
Favorite
PII-089 - POPULATION PHARMACOKINETICS OF ORAL MELTDOSE TACROLIMUS (LCPT) IN DE NOVO KIDNEY TRANSPLANT PATIENTS.
Xiaoying Huang
Favorite
PT-027 - UTILIZING ADAPTIVE DOSING SIMULATIONS AND MACHINE LEARNING TO IMPROVE PREDICTION AND MANAGEMENT OF NEUTROPENIA RATES.
Xiaoying Huang
Favorite
Hua, Shuangcheng

AbbVie
PT-020 - CONSTRUCTING EXTERNAL CONTROL (EC) ARMS FOR ORGAN IMPAIRMENT (OI) STUDIES: COMPARING STATISTICAL MATCHING AND POOLING METHODS
Shuangcheng Hua
Favorite
PWII-005 - CONSTRUCTING EXTERNAL CONTROL (EC) ARMS FOR ORGAN IMPAIRMENT (OI) STUDIES: COMPARING STATISTICAL MATCHING AND POOLING METHODS
Shuangcheng Hua
Favorite
Huynh, Julie

UCSD
PII-117 - DRUG DEVELOPMENT CONSIDERATIONS FOR DRUG-DRUG INTERACTION STUDIES WITH FLUCONAZOLE AS A SIMULTANEOUS INHIBITOR OF MULTIPLE METABOLIC ENZYMES.
Julie Huynh
Favorite
Hu, Henry

Merck
PI-068 - EXPOSURE-RESPONSE ANALYSIS OF MK-5475 IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
Henry Hu
Favorite
Hu, Ziheng

Merck & Co.
PI-084 - POPULATION PHARMACOKINETIC ANALYSIS OF SOTATERCEPT IN JAPANESE HEALTHY PARTICIPANTS AND JAPANESE PARTICIPANTS WITH PULMONARY ARTERIAL HYPERTENSION.
Ziheng Hu
Favorite
I
Iakovleva, Tatiana

University of Florida
PI-090 - PROTEIN BINDING: STATIC SOLUTIONS TO A DYNAMIC PROBLEM CAN BE MISLEADING IN DRUG DEVELOPMENT AND REGULATORY EVALUATION.
Tatiana Iakovleva
Favorite
Ibrahim, Safaa

Applied Pharmacometrics Training – Africa Program, c/o Pharmacometrics Africa NPC
PI-120 - LEVERAGING MACHINE LEARNING FOR HIGH-DIMENSIONAL COVARIATE SCREENING IN ALZHEIMER'S DISEASE PROGRESSION MODELING.
Safaa Ibrahim
Favorite
Imam, Sabrina

University of Chicago
PII-018 - INTESTINAL MICROBIOME AND METABOLOME FLUCTUATIONS IN PATIENTS RECEIVING INTENSE CHEMOTHERAPY FOR AML: RESULTS FROM A PILOT, PROSPECTIVE OBSERVATIONAL STUDY
Sabrina Imam
Favorite
Itohara, Kotaro

Department of Pharmacy, Kobe University Hospital
PII-101 - PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL ANALYSIS OF ANTIPSYCHOTICS BEFORE AND AFTER CHILDBIRTH.
Kotaro Itohara
Favorite
Izat, Nihan

The University of Manchester
PI-002 - APPLICATION OF VIRTUAL TWIN PBPK MODELS IN OBESE WITH CYP3A4 PHENOTYPING USING ENDOGENOUS BIOMARKER DATA.
Nihan Izat
Favorite
J
Jafari, Eissa

Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, Florida.
PI-127 - EFFECT OF HYPERTENSION (HTN) AND BLOOD PRESSURE (BP) CONTROL ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH ALZHEIMER'S DISEASE AND RELATED DEMENTIA (ADRD) WITHIN THE STATE OF FLORIDA USING ELECTRONIC HEALTH RECORD (EHR)-BASED DATA.
Eissa Jafari
Favorite
Jain, Manav

University of Utah
LB-013 - PHARMACOKINETIC EVALUATION OF A NATURAL HEMP EXTRACT-BASED COSMETIC PRODUCT AFTER TOPICAL AND ORAL ADMINISTRATIONS.
Manav Jain
Favorite
JAMOIS, CANDICE

Pharma Research and Early Development, Roche Innovation Center Basel
LB-004 - COUPLING BIOMARKER KNOWLEDGE WITH THE STRENGTHS OF PHARMACOMETRICS AND MACHINE LEARNING FOR INDIVIDUAL PROGNOSIS IN ONCOLOGY: A PRECISION MEDICINE FRAMEWORK FOR HEALTH CARE PROVIDERS
CANDICE JAMOIS
Favorite
PI-037 - QUANTITATIVE CLINICAL PHARMACOLOGY SUPPORTS TOTALITY OF EVIDENCE, DATA INTEGRATION AND DOSE SELECTION PROPOSAL OF A NEW MOLECULAR ENTITY WITH NO SINGLE AGENT ACTIVITY DEVELOPED IN COMBINATION: CASE STUDY OF ENGLUMAFUSP ALFA
CANDICE JAMOIS
Favorite
Jappar, Dilara

Boehringer Ingelheim Pharmaceuticals Inc.
PI-080 - PHARMACOKINETICS OF NERANDOMILAST IN HEALTHY VOLUNTEERS
Dilara Jappar
Favorite
Jones, Austin

Virginia Commonwealth University
PI-021 - THE EFFECTS OF OPIOIDS ON BLOOD-BRAIN BARRIER INTEGRITY, ANTIRETROVIRAL ACCUMULATION, AND NEUROINFLAMMATORY CHEMOKINE PROFILES IN ECOHIV-INFECTED MICE
Austin Jones
Favorite
Jung, Dahee

University of Illinois Chicago
PI-003 - BIOMARKER UTILIZATION IN NEUROLOGICAL DRUG PRODUCTS APPROVED BY FDA (2008-2023): A LANDSCAPE ANALYSIS.
Dahee Jung
Favorite
K
Kang, Jaegu

Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea
PII-091 - SAFETY, PHARMACODYNAMICS, AND PHARMACOKINETICS OF IN-115314, A NOVEL SELECTIVE JAK1 INHIBITOR, AFTER A SINGLE OR MULTIPLE ORAL ADMINISTRATION IN HEALTHY MALE PARTICIPANTS.
Jaegu Kang
Favorite
Kang, Sanghoon

University of Florida College of Pharmacy Department of Pharmaceutics
OAII-001 - AI/ML DERIVED MAGNETIC RESONANCE BIOMARKERS FOR BONE FRAGILITY IN DUCHENNE MUSCULAR DYSTROPHY
Sanghoon Kang
Favorite
PT-018 - AI/ML DERIVED MAGNETIC RESONANCE BIOMARKERS FOR BONE FRAGILITY IN DUCHENNE MUSCULAR DYSTROPHY
Sanghoon Kang
Favorite
Karibe, Tsuyoshi

Daiichi Sankyo
PI-038 - REVERSE-TRANSLATIONAL FINDINGS FOR DATOPOTAMAB DERUXTECAN (DATO-DXD) HUMAN EFFICACIOUS DOSE PREDICTION BASED ON MECHANISTIC PK/TUMOR GROWTH INHIBITION ANALYSIS FOR PATIENT-DERIVED AND CANCER CELL LINE-DERIVED XENOGRAFT MICE.
Tsuyoshi Karibe
Favorite
Kasten, Anne

Institute of Experimental and Clinical Pharmacology
PI-022 - A CRISPR/CAS9-DERIVED ABCB1/ABCG2 KNOCKOUT PLATFORM FOR SUBSTRATE CHARACTERIZATION.
Anne Kasten
Favorite
Kathman, Steven

CSL Behring
PI-082 - POPULATION PHARMACOKINETIC (PK)-PHARMACODYNAMIC (PD) MODELING OF ANUMIGILIMAB, A MONOCLONAL ANTIBODY THAT BLOCKS G-CSF BINDING TO THE G-CSF RECEPTOR
Steven Kathman
Favorite
Killam, Shayna

L.S. Skaggs Institute for Health Innovation - University of Montana
PII-112 - GENETIC PREDICTORS OF RESPONSE TO RISPERIDONE IN CHILDREN AND ADOLESCENTS: INSIGHTS FROM A PSYCHIATRIC HOSPITAL SERVING RURAL AND UNDERSERVED YOUTH
Shayna Killam
Favorite
Kim, Yurim

FDA
PT-022 - LABELING INFORMATION ON SPECIFIC POPULATIONS FOR NEW MOLECULAR ENTITIES APPROVED BETWEEN 2018 AND 2020
Yurim Kim
Favorite
Kirouac, Daniel

Metrum Research Group
PI-125 - QUANTITATIVE SYSTEMS PHARMACOLOGY MODELING OF LONCASTUXIMAB TESIRINE-LPYL COMBINED WITH T CELL-DEPENDENT BISPECIFIC ANTIBODIES BRIDGES KNOWLEDGE AND DOSE REGIMEN STRATEGY FOR PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA
Daniel Kirouac
Favorite
Knight, Beverly

Johnson & Johnson Innovative Medicine
PII-056 - ADME PROFILING OF TARGETED ORAL PEPTIDE JNJ-77242113
Beverly Knight
Favorite
Koo, Hyunwoo

Indiana University School of Medicine and Purdue University College of Pharmacy
PII-042 - ANALYSIS OF A CLINICAL PROGRAM TO RETURN CLINICALLY ACTIONABLE PHARMACOGENETIC INFORMATION FROM GERMLINE DNA SEQUENCING DATA GENERATED IN MOLECULAR TUMOR BOARDS: WORKFLOW AND ESTIMATED COSTS
Hyunwoo Koo
Favorite
Krol, Thomas

STAT Therapeutics, Inc
PI-091 - THE DORSAL FOREARM AS A NOVEL TARGET FOR INTRAMUSCULAR INJECTIONS: CLINICAL PHARMACOKINETIC RESULTS.
Thomas Krol
Favorite
Kronfol, Mohamad

U.S. Food and Drug Administration
PI-116 - APPRAISAL OF PHARMACODYNAMIC CLAMP STUDY DESIGN FOR GLP-1 RECEPTOR AGONISTS.
Mohamad Kronfol
Favorite
L
Ladumor, Mayur K.

Merck & Co.
PII-023 - PBPK MODEL DEVELOPMENT AND VALIDATION FOR ROSUVASTATIN: INTEGRATING IN VITRO, CLINICAL PHARMACOKINETIC, AND LIVER PET IMAGING DATA TO IMPROVE PREDICTIONS OF OATP1B- AND BCRP-MEDIATED DRUG-DRUG INTERACTIONS
Mayur K. Ladumor
Favorite
Le Merdy, Maxime

Simulations Plus, Inc.
PI-101 - PREDICTING BRINZOLAMIDE OCULAR RESPONSE IN HUMANS USING AN OCULAR PBPK-PD MODELING AND SIMULATION
Maxime Le Merdy
Favorite
Le, An

University of Pittsburgh
PT-002 - DETERMINING CRITICAL PHYSIOLOGICAL AND DRUG SPECIFIC PARAMETERS FOR ENHANCING A PHYSIOLOGICALLY-BASED PHARMACOKINETICS MODEL FOR THE FEMALE REPRODUCTIVE TRACT
An Le
Favorite
PWI-001 - DETERMINING CRITICAL PHYSIOLOGICAL AND DRUG SPECIFIC PARAMETERS FOR ENHANCING A PHYSIOLOGICALLY-BASED PHARMACOKINETICS MODEL FOR THE FEMALE REPRODUCTIVE TRACT
An Le
Favorite
Lee, Mark

Daiichi Sankyo
PI-062 - CONCENTRATION-QTC ANALYSIS OF PATRITUMAB DERUXTECAN IN PATIENTS WITH HER3-EXPRESSING METASTATIC BREAST CANCER OR METASTATIC OR UNRESECTABLE NON-SMALL CELL LUNG CANCER
Mark Lee
Favorite
Lee, seungri

Seoul National University College of Medicine
PII-121 - PHARMACOKINETICS AND SAFETY OF NANOPARTICLE FENOFIBRATE (AD-104-A) IN RENAL IMPAIRMENT PATIENTS.
seungri Lee
Favorite
LEMAITRE, Florian

Rennes University Hospital, Rennes, France
PII-105 - EFFECT OF P-GLYCOPROTEIN INHIBITION ON TWO TACROLIMUS FORMULATIONS: A RANDOMIZED, 4-SEQUENCE, CROSS-OVER, DRUG-DRUG INTERACTION STUDY
Florian LEMAITRE
Favorite
Le, Sunny

Biopharma Services
PII-013 - EVALUATING DRUG-DRUG INTERACTIONS WITH ACID-REDUCDING AGENTS: INSIGHTS FROM FDA GUIDANCE AND RECENT APPROVALS
Sunny Le
Favorite
Lennox, Ashley

Geron Corporation
PII-033 - NO EFFECT OF IMMUNOGENICITY ON THE PHARMACOKINETICS, EFFICACY, AND SAFETY OF THE NOVEL OLIGONUCLEOTIDE TELOMERASE INHIBITOR IMETELSTAT IN LOWER-RISK MYELODYSPLASTIC SYNDROMES
Ashley Lennox
Favorite
Letscher, Emily

University of Minnesota
PI-105 - EFFECT OF INDUCED HYPOGLYCEMIA ON OXIDATIVE STRESS IN HEALTHY VOLUNTEERS AND THE POTENTIAL APPLICATIONS OF N-ACETYLCYSTEINE
Emily Letscher
Favorite
Levi, Micha

Bill and Melinda Gates Medical Research Institute
PII-015 - MODELING AND SIMULATION ANALYSIS TO SUPPORT DOSE SELECTION FOR MAM01, A NOVEL ANTI-CIRCUMSPOROZOITE PROTEIN MONOCLONAL ANTIBODY, IN UPCOMING TRIALS
Micha Levi
Favorite
Li, Dan

Merck
PII-084 - POPULATION PHARMACOKINETIC ANALYSIS OF MK-5475 IN HEALTHY PARTICIPANTS AND PATIENTS WITH PULMONARY HYPERTENSION
Dan Li
Favorite
Li, Jing

Karmanos Cancer Institute
PI-097 - MECHANISTIC MODELING OF SPATIAL HETEROGENEITY OF DRUG PENETRATION AND EXPOSURE IN THE HUMAN CENTRAL NERVOUS SYSTEM AND BRAIN TUMORS
Jing Li
Favorite
Li, Lang

The Ohio State University
PII-113 - PHARMACOTHERAPY RESEARCH LANDSCAPE AND KNOWLEDGE GAP FOR OPIOIDS AMONG THE MATERNAL AND PEDIATRIC POPULATIONS
Lang Li
Favorite
Lim, Chay Ngee

Pfizer Inc
PI-110 - A PHASE 1, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF A SINGLE DOSE OF RIMEGEPANT IN CHILDREN (>=6 TO <12 YEARS OF AGE) WITH A HISTORY OF MIGRAINE
Chay Ngee Lim
Favorite
Li, Mengyao

Bicycle Therapeutics, Inc.
PII-090 - POPULATION PK (POPPK) AND EXPOSURE-SAFETY (E-S) ANALYSIS OF BT5528, A BICYCLE TOXIN CONJUGATE (BTC®), IN PATIENTS WITH ADVANCED SOLID TUMORS ASSOCIATED WITH EPHA2 EXPRESSION.
Mengyao Li
Favorite
Li, Min

RemeGen Co., Ltd.
PI-028 - CLINICAL PHARMACOKINETICS AND BIOMARKER ANALYSES OF RC88, A NEW MESOTHELIN-TARGETING ANTIBODY DRUG CONJUGATE, IN PATIENTS WITH ADVANCED SOLID TUMORS
Min Li
Favorite
Lim, SoHyeon

Seoul National University
PI-107 - OPTIMIZING VANCOMYCIN DOSING REGIMENS FOR OBESE PATIENTS
SoHyeon Lim
Favorite
Li, Shuxia

The First Affiliated Hospital of Sun Yat-sen University
PI-112 - ESTIMATION OF THE AREA UNDER THE CURVE OF MYCOPHENOLIC ACID CONCENTRATION IN CHINESE PEDIATRIC RENAL TRANSPLANT PATIENTS USING LIMITED SAMPLING METHOD.
Shuxia Li
Favorite
Liu, Can

Bristol Myers Squibb
PII-068 - EXPOSURE-RESPONSE ANALYSES FOR EFFICACY AND SAFETY OF BMS-986365, A DUAL ANDROGEN RECEPTOR LIGAND-DIRECTED DEGRADER AND ANTAGONIST, IN PATIENTS WITH PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Can Liu
Favorite
Liu, Han

Uppsala University
PII-031 - INFORMATIVE CENSORING BIAS IN DOSE-RESPONSE ANALYSIS OF PROGRESSION-FREE SURVIVAL OF ANTICANCER DRUGS
Han Liu
Favorite
Li, Yang

Merck & Co., Inc.
E-002 - REDUCTION IN ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) OBSERVED WITH DORAVIRINE (DOR) IS CAUSED BY INHIBITION OF ORGANIC CATION TRANSPORTER 2 (OCT2)
Yang Li
Favorite
Li, Ziran

University of California, San Francisco
OAII-003 - APPLYING ARTIFICIAL INTELLIGENCE-BASED DIGITAL TWINS IN TUBERCULOSIS CLINICAL TRIALS
Ziran Li
Favorite
PI-089 - POPULATION PHARMACOKINETICS OF PYRAZINAMIDE FOR PATIENTS WITH MULTIDRUG RESISTANT TUBERCULOSIS
Ziran Li
Favorite
PT-019 - APPLYING ARTIFICIAL INTELLIGENCE-BASED DIGITAL TWINS IN TUBERCULOSIS CLINICAL TRIALS
Ziran Li
Favorite
Lyu, Xintian

University of Minnesota
PII-057 - AN AUTOMATED COMPARISON PLATFORM FOR INFORMED DRUG LABELING DECISIONS: WEIGHT-BASED DOSING VS. WEIGHT-BANDED DOSING.
Xintian Lyu
Favorite
M
Madden, Molly

Edgewise Therapeutics
PI-077 - PHARMACOKINETIC ANALYSIS OF SEVASEMTEN IN A PHASE 1 STUDY IN HEALTHY SUBJECTS AND BECKER MUSCULAR DYSTROPHY PATIENTS
Molly Madden
Favorite
PII-054 - A PHASE 1, OPEN-LABEL STUDY IN HEALTHY MALE SUBJECTS OF THE ABSORPTION, METABOLISM, EXCRETION, AND PHARMACOKINETICS OF SEVASEMTEN
Molly Madden
Favorite
Maglalang, Patty

University of North Carolina at Chapel Hill
PI-100 - PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING TO CHARACTERIZE THE DISPOSITION OF TOPIRAMATE IN CHILDREN WITH AND WITHOUT OBESITY USING REAL-WORLD DATA.
Patty Maglalang
Favorite
Magnas, Paulette

URP 7323, Cochin Hospital, Paris Cité University
PI-088 - POPULATION PHARMACOKINETICS OF ELEXACAFTOR, TEZACAFTOR AND IVACAFTOR IN REAL WORLD ADULT PATIENTS WITH CYSTIC FIBROSIS
Paulette Magnas
Favorite
Malave, Jean

University of Florida
PII-050 - IMPACT OF SOCIAL DETERMINANTS OF HEALTH COMPOSITE MEASURES ON OUTCOMES AFTER PCI IN P2Y12 INHIBITOR-TREATED PATIENTS
Jean Malave
Favorite
Marchetti, Luca

Fondazione The Microsoft Research - University of Trento Centre for Computational and Systems Biology (COSBI)
PII-122 - A COMPUTATIONAL PLATFORM TO SUPPORT THE DEVELOPMENT OF MRNA-BASED VACCINES AND THERAPEUTICS.
Luca Marchetti
Favorite
Marín-Goñi, Irene

Mayo Clinic / CIMA University of Navarra
PI-039 - TARGETING OF CDK12/13 AND ANDROGEN PATHWAYS IN MESTASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Irene Marín-Goñi
Favorite
Marrero-Polanco, Jean

Mayo Clinic
PI-004 - DIGITAL HEALTH BIOMARKERS FOR CHARACTERIZING DEPRESSION SEVERITY TRAJECTORIES DURING ANTIDEPRESSANT TREATMENT.
Jean Marrero-Polanco
Favorite
McComb, Mason

Amgen
PII-035 - PHARMACOKINETICS OF AMG 193 (A SMALL MOLECULE MTA-COOPERATIVE PRMT5 INHIBITOR) AFTER SINGLE AND MULTIPLE DOSING IN THE FASTED AND FED IN STATE PATIENTS WITH MTAP DELETED TUMORS
Mason McComb
Favorite
Miller, Emily

Virginia Commonwealth University
PII-017 - EFFECTS OF HIV AND OPIOIDS ON CHEMOKINE EXPRESSION IN AN INFECTIOUS MOUSE MODEL
Emily Miller
Favorite
Mittal, Anjali

Simulations Plus
PII-124 - PREDICTION OF CLINICAL OUTCOMES IN A HETEROGENOUS NSCLC VIRTUAL PATIENT POPULATION: A QUANTITATIVE SYSTEMS PHARMACOLOGY APPROACH.
Anjali Mittal
Favorite
Mok, Marilyn

Edgewise Therapeutics
PI-079 - PHARMACOKINETICS OF EDG-7500, A FIRST-IN-CLASS CARDIAC SARCOMERE MODULATOR FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
Marilyn Mok
Favorite
Montalvo, Abelardo

University of Florida College of Pharmacy
PII-049 - IDENTIFYING FUNCTIONAL REGULATORY SNPS THAT REGULATE CYP2C9 EXPRESSION TO OPTIMIZE CYP2C9 BIOMARKER PANELS.
Abelardo Montalvo
Favorite
Morales Junior, Ronaldo

Cincinnati Children's Hospital Medical Center
PT-012 - FROM PICU TO NICU: REFINING MATURATION FACTOR FOR MEROPENEM CLEARANCE.
Ronaldo Morales Junior
Favorite
PWI-005 - FROM PICU TO NICU: REFINING MATURATION FACTOR FOR MEROPENEM CLEARANCE.
Ronaldo Morales Junior
Favorite
Morcos, Peter

-
PI-033 - MULTISTATE MODEL TO INVESTIGATE OVERALL SURVIVAL (OS) FROM COPANLISIB PIVOTAL TRIALS.
Peter Morcos
Favorite
Mukker, Jatinder

EMD Serono
PII-026 - AN INTEGRATED PK/PD MODELING FRAMEWORK OF NONCLINICAL EFFICACY AND CLINICAL HEMATOLOGICAL SAFETY TO INFORM DOSE SELECTION OF ATRI TUVUSERTIB IN COMBINATION WITH NIRAPARIB IN PATIENTS WITH PARPI-RESISTANT OVARIAN CANCER
Jatinder Mukker
Favorite
Murray, Bernard

Gilead Sciences
PI-019 - LOW POTENTIAL FOR DRUG INTERACTION BETWEEN LENACAPAVIR AND FENTANYL.
Bernard Murray
Favorite
N
Nader, Ahmed

Clinical Pharmacology, Modelling and Simulation, GSK
PII-020 - SIMILAR BIOAVAILABILITY OF SUBCUTANEOUS BEPIROVIRSEN WHEN DELIVERED FROM A VIAL OR PREFILLED SYRINGE FITTED WITH A SAFETY SYRINGE DEVICE IN HEALTHY ADULT PARTICIPANTS
Ahmed Nader
Favorite
Naderer, Odin

Chimerix, Inc.
PI-040 - THE EFFECT OF DORDAVIPRONE (ONC201) ON CARDIAC REPOLARIZATION IN HEALTHY ADULT PARTICIPANTS
Odin Naderer
Favorite
Nahid, Noor

Ohio State University
PII-043 - ASSOCIATION BETWEEN CYP2D6 GENOTYPE-INHIBITOR INTERACTIONS AND PAIN-RELATED EMERGENCY DEPARTMENT VISITS IN CYP2D6-OPIOID-TREATED PATIENTS
Noor Nahid
Favorite
Nakhla, Keroles

BMS
PI-026 - A STUDY TO EVALUATE RELATIVE BIOAVAILABILITY OF THREE NAPAROFENIB (LXH254) FORMULATIONS IN HEALTHY SUBJECTS
Keroles Nakhla
Favorite
PII-110 - AN OVERVIEW OF FOOD EFFECT STUDIES IN PEDIATRIC POPULATION SUBMITTED TO U.S. FOOD AND DRUG ADMINISTRATION (FDA) (2004-2024)
Keroles Nakhla
Favorite
Natesan, Divya

University of Pittsburgh, School of Medicine
PI-034 - ONCOLOGIST CONSIDERATIONS WHEN CHOOSING BETWEEN 200 MG EVERY-3-WEEK VERSUS 400 MG EVERY-6-WEEK DOSING OF PEMBROLIZUMAB MONOTHERAPY WITHIN UPMC HILLMAN CANCER CENTER NETWORK
Divya Natesan
Favorite
Nayak, Satyaprakash

Pfizer Inc.
PII-106 - POPULATION PK AND PK/PD MODELING OF MARSTACIMAB, AN ANTI-TFPI MONOCLONAL ANTIBODY, IN ADULT AND ADOLESCENT HEMOPHILIA PATIENTS WITHOUT INHIBITORS
Satyaprakash Nayak
Favorite
Neal, Reem

UT Southwestern Medical Center
PI-007 - PROTEOMIC SIGNATURES IN THE CEREBROSPINAL FLUID (CSF) OF INDIVIDUALS WITH PRECLINICAL AND PRODROMAL ALZHEIMER'S DISEASE (AD): A KEY ROLE FOR ENDOTHELIAL AND ADHESION PROTEINS IN PRECLINICAL AD.
Reem Neal
Favorite
Neuhoff, Sibylle

Certara UK
LB-018 - BUILDING AN OAT-MATRIX: PERFORMANCE VERIFICATION OF IVIVE-PBPK MODELS IN THE PREDICTION OF OAT1/OAT3 MEDIATED DRUG-DRUG INTERACTIONS
Sibylle Neuhoff
Favorite
PII-002 - APPLICATIONS AND LIMITATIONS OF 4ΒETA-HYDROXYCHOLESTEROL AS A SENSITIVE ENDOGENOUS BIOMARKER
Sibylle Neuhoff
Favorite
Ngara, Bernard

University of California San Francisco
PI-061 - CLOFAZIMINE PHARMACOKINETICS FOR MULTIDRUG-RESISTANT TB: IMPLICATION OF NOVEL COMBINATION REGIMENS.
Bernard Ngara
Favorite
PII-093 - TRANSLATIONAL MODELING OF BTZ-043 IN PREDICTING PHASE IIA EFFICACY AND EVALUATION OF DRUG-DRUG INTERACTIONS WITH BPAL IN MURINE MODELS
Bernard Ngara
Favorite
Nguyen, Chi Huu

X4 Pharmaceuticals (Austria) GmbH, Vienna, Austria
E-006 - CXCR4 ANTAGONISM CORRECTS PERIPHERAL NEUTROPENIA IN A MOUSE MODEL OF WHIM SYNDROME.
Chi Huu Nguyen
Favorite
Nguyen, Duyen

U.S. Food and Drug Administration
PI-109 - IMPACT OF RISK EVALUATION AND MITIGATION STRATEGY PROGRAMS ON PRODUCT-SPECIFIC GUIDANCES FOR GENERIC DRUG DEVELOPMENT
Duyen Nguyen
Favorite
Nguyen, Thomas

University at Buffalo, School of Pharmacy & Pharmaceutical Sciences, Division of Clinical & Translational Therapeutics
PII-021 - VIRAL VANGUARD: TURNING THE TIDE AGAINST SUPERBUGS
Thomas Nguyen
Favorite
Nishii, Rina

Bristol Myers Squibb
PII-004 - EVALUATING THE UTILITY OF ENDOGENOUS OCT2 AND MATE1/2-K BIOMARKERS FOR EARLY DDI ASSESSMENT IN ONCOLOGY PHASE 1 STUDIES
Rina Nishii
Favorite
Nittu, Satyavardhan Rao

University of Florida
PII-046 - GENETIC VARIANTS PREDICTIVE OF FEBRILE NEUTROPENIA DURING INDUCTION I IN PEDIATRIC ACUTE MYELOID LEUKEMIA PATIENTS
Satyavardhan Rao Nittu
Favorite
Norris, Madeline

University of Florida
PI-042 - AREAS OF CLINICAL RELEVANCE AND PHARMACOGENE ACTIONABILITY FOR PATIENTS FROM A PHARMACIST-LED, VIRTUAL PHARMACOGENETICS CONSULTATION CLINIC.
Madeline Norris
Favorite
TIP-002 - EVALUATION OF A PHARMACIST-LED PHARMACOGENETICS CONSULTATION SERVICE ON HEALTHCARE COSTS AND OUTCOMES.
Madeline Norris
Favorite
O
Obied, Taghrid

Syneos Health
PII-012 - CONSIDERATIONS FOR PHASE 1 CLINICAL TRIALS IN ADULT PATIENTS
Taghrid Obied
Favorite
Odujinrin, Dolapo

King’s College London
PII-034 - OPTIMIZING DOSE SELECTION FOR CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY IN THE TREATMENT OF PATIENTS WITH CANCER : A SYSTEMATIC REVIEW OF MECHANISTIC IN SILICO MODELS.
Dolapo Odujinrin
Favorite
Okuneye, Kamaldeen

Incyte Research Institute
PII-032 - MOVING TOWARD "FIT-FOR-PURPOSE" QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODELING IN DRUG DEVELOPMENT: CASE EXAMPLES IN ONCOLOGY.
Kamaldeen Okuneye
Favorite
Oliveira, Daniel

University of North Carolina Chapel Hill / Certara
PI-052 - A MODELING APPROACH TO EXPEDITE THE DEVELOPMENT OF A NEW LONG-ACTING CONTROLLED-RELEASE MULTIPURPOSE FORMULATION CONTAINING MEDROXYPROGESTRONE ACETATE
Daniel Oliveira
Favorite
Omura, Tomohiro

Department of Pharmacy, Kobe University Hospital
PII-008 - MICRORNA REGULATING SEL1L INVOLVED IN THE PATHOGENESIS OF PARKINSON'S DISEASE AND ITS EXPRESSION LEVELS IN PATIENT PLASMA.
Tomohiro Omura
Favorite
Ouyang, Jiayi

The Ohio State University
PI-118 - DRUG-INDUCED ADE PREDICTION MODEL PERFORMANCE DEPENDS ON STATISTICAL MODELS AND STATISTICALLY SIGNIFICANT THRESHOLDS FOR DRUG-INDUCED ADE DATA
Jiayi Ouyang
Favorite
P
Paglialunga, Sabina

Celerion
PII-014 - SAFETY , TOLERABILITY, AND PHARMACOKINETICS OF SM17 IN HEALTHY VOLUNTEERS, A NOVEL IL-17 RECEPTOR B TARGETING ANTIBODY IN PHASE I DEVELOPMENT FOR THE TREATMENT OF ASTHMA
Sabina Paglialunga
Favorite
Pal, Arindom

U.S. Food and Drug Administration
PI-099 - PBPK MODELING TO SUPPORT THE EXPANSION OF BIOWAIVER TO NON-Q1/Q2 BCS CLASS III DRUG PRODUCTS.
Arindom Pal
Favorite
Paleja, Bhairav

VANTAGE RESEARCH
E-003 - A QUANTITATIVE SYSTEMS PHARMACOLOGY QSP) MODEL FRAMEWORK FOR COMBINED CLINICAL EFFICACY AND HEMATOLOGICAL TOXICITY PRECITIONS FOR ANTIBODY DRUG CONJUGATES.
Bhairav Paleja
Favorite
E-004 - DEVELOPMENT OF QSP PLATFORM MODEL FOR PREDICTING CLINICAL EFFICACY AND CRS INCIDENCE OF CD3 BISPECIFICS IN STEAP1 PROSTATE CANCER
Bhairav Paleja
Favorite
Pan, Xian

Certara
PII-097 - MECHANISTIC INSIGHTS INTO CYTOKINE ANTAGONIST-DRUG INTERACTIONS: A PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING APPROACH WITH TOCILIZUMAB AS A CASE STUDY
Xian Pan
Favorite
Paydary, Koosha

Rush University Medical Center, Department of Medicine, Section of Hematology, Oncology and Cell Therapy
PII-037 - REAL-WORLD CHARACTERIZATION OF DRUG-DRUG INTERACTIONS AMONG PATIENTS WITH ONCOGENE-DRIVEN NON-SMALL CELL LUNG CANCER USING TYROSINE KINASE INHIBITORS
Koosha Paydary
Favorite
Pillay-Fuentes Lorente, Veshni

Division of Clinical Pharmacology, Department of Medicine, Stellenbosch University
PI-060 - CHARACTERIZING COLISTIN PHARMACOKINETICS FOLLOWING A LOADING DOSE: FIRST DESCRIPTION IN AN AFRICAN COHORT.
Veshni Pillay-Fuentes Lorente
Favorite
Piscitelli, Joseph

Pfizer, Inc.
PI-010 - LIMITED SAMPLING STRATEGIES FOR NONCOMPARTMENTAL ANALYSES OF ENCORAFENIB PHARMACOKINETIC DATA
Joseph Piscitelli
Favorite
PI-036 - POPULATION PHARMACOKINETIC MODELING OF SUNITINIB AND SU12662 IN PATIENTS WITH SOLID TUMORS
Joseph Piscitelli
Favorite
Purohit, Dvijen

University of California, San Francsico
PI-015 - IMPACT OF RIFAMPICIN DOSE ON LINEZOLID PHARMACOKINETICS IN TUBERCULOUS MENINGITIS: INSIGHTS FROM THE ALTER TRIAL
Dvijen Purohit
Favorite
Q
Qian, Lixuan

York College, City University of New York
LB-003 - EXPLORING Δ-9-TETRAHYDROCANNABINOL (THC) INDUCED “FEELING HIGH” USING A PHYSIOLOGICALLY BASED PHARMACOKINETIC-PHARMACODYNAMIC MODEL
Lixuan Qian
Favorite
LB-016 - QUANTIFYING HEART RATE CHANGES AFTER Δ-9-TETRAHYDROCANNABINOL (THC) ADMINISTRATION USING A PBPK-PD MODEL IN HEALTHY ADULTS
Lixuan Qian
Favorite
LB-017 - ASSESSING THE IMPACT OF AGE ON CANNABINOID DISPOSITION
Lixuan Qian
Favorite
Quickfall, Danica

University of Chicago
PII-016 - CHARACTERIZATION AND PHARMACOKINETIC MODELLING OF VANCOMYCIN IN CRITICALLY ILL ICU PATIENTS UNDERGOING CVVHD
Danica Quickfall
Favorite
TIP-003 - PILOT STUDY ON VANCOMYCIN ADMINISTRATION VIA DIALYSATE IN PATIENTS RECEIVING CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT)
Danica Quickfall
Favorite
R
Rababah, Abeer

Mayo Clinic
PII-102 - PREDICTING THE EXPOSURE OF IRINOTECAN AND ITS ACTIVE METABOLITE (SN-38) IN CANCER PATIENTS USING PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING.
Abeer Rababah
Favorite
Ramesh, Shyam

University of Florida
PT-014 - UTILIZING A DISEASE PROGRESSION MODEL TO DEVELOP A CLINICAL TRIAL SIMULATION TOOL THAT OPTIMIZES TRIAL DESIGN FOR AUTOSOMAL DOMINANT TUBULOINTERSTITIAL KIDNEY DISEASE.
Shyam Ramesh
Favorite
RATH, SEEPRARANI

Rutgers, the State University of New Jersey
PII-108 - STREAMLINING POTENCY ASSESSMENT OF TOPICAL CORTICOSTEROIDS USING VASOCONSTRICTOR ASSAY (VCA)
SEEPRARANI RATH
Favorite
Rhiani, Sweilem

Moderna, Inc.
PI-093 - TRANSLATIONAL PHARMACOKINETIC/PHARMACODYNAMIC MODEL FOR NOVEL MRNA-MODALITY SUPPORTING ENZYME REPLACEMENT THERAPY.
Sweilem Rhiani
Favorite
Riselli, Andrew

University of California, San Francisco
PT-004 - INTEGRATING BIOMARKERS AND PBPK MODELING TO UNCOVER THE MECHANISM OF A MULTI-TRANSPORTER DDI.
Andrew Riselli
Favorite
PWII-003 - INTEGRATING BIOMARKERS AND PBPK MODELING TO UNCOVER THE MECHANISM OF A MULTI-TRANSPORTER DDI.
Andrew Riselli
Favorite
Roffel, Ad

ICON plc
PI-013 - CONSIDERATIONS ON HUMAN ADME STUDIES AND PROPOSED DECISION TREE TOWARDS TAILORED STUDY DESIGNS.
Ad Roffel
Favorite
Rowland Yeo, Karen

Certara UK Ltd
PII-114 - RELATIVE IMPACT OF CYP2D6 GENOTYPE PHENOTYPE ON EXPOSURE OF SSRIS DURING PREGNANCY: EXTRAPOLATION APPROACH USING RWD AND PBPK MODELLING
Karen Rowland Yeo
Favorite
S
Sadighi, Armin

AbbVie
PI-024 - PROMISING CAPACITY OF MACHINE LEARNING MODELS TO PREDICT OATP1B1- AND OATP1B3-MEDIATED INHIBITION POTENTIAL IN EARLY DRUG DISCOVERY.
Armin Sadighi
Favorite
Safgren, Stephanie

Mayo Clinic
PI-069 - FIRST IN HUMAN POPULATION PHARMACOKINETIC ANALYSIS OF THE EGFR INHIBITOR WSD0922-FU.
Stephanie Safgren
Favorite
Schmith, Virginia (Ginny)

Schmith PK/PD Consulting LLC and Syntegrity Quantitative Clinical Pharmacology Collaborative
LB-012 - EVALUATION OF THE EFFECT OF CYP3A4 AND P-GLYCOPROTEIN INHIBITION BY ITRACONAZOLE OR INDUCTION BY RIFAMPICIN ON THE PHARMACOKINETICS OF ECOPIPAM AND ITS METABOLITES
Virginia (Ginny) Schmith
Favorite
Schmitt, Vanessa

Abbvie
PI-055 - A SEMI-MECHANISTIC PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MODEL OF ABBV-383 CHARACTERIZING THE INTERPLAY BETWEEN SOLUBLE BCMA (SBMCA) AND FREE AND TOTAL PK.
Vanessa Schmitt
Favorite
Shabnaz, Samia

University of Florida
OAI-002 - EVALUATION OF CAUSAL INFERENCE OF BILE ACIDS ON CARFILZOMIB RELATED CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH MULTIPLE MYELOMA BY MENDELIAN RANDOMIZATION
Samia Shabnaz
Favorite
PT-007 - EVALUATION OF CAUSAL INFERENCE OF BILE ACIDS ON CARFILZOMIB RELATED CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH MULTIPLE MYELOMA BY MENDELIAN RANDOMIZATION
Samia Shabnaz
Favorite
Shahin, Mohamed

Pfizer Research & Development
PI-076 - PATIENT-CENTRIC MICROSAMPLING VERSUS TRADITIONAL BLOOD SAMPLING: A PHARMACOKINETIC STUDY OF ZAVEGEPANT
Mohamed Shahin
Favorite
Shao, Danwei

University of North Carolina at Chapel Hill
PI-049 - IMPACT OF CYP2C19 AND CYP3A INHIBITORS ON CLOPIDOGREL CLINICAL EFFECTIVENESS IN CYP2C19 GENOTYPED PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI) IN A REAL-WORLD SETTING.
Danwei Shao
Favorite
Sharma, Sheena

Bristol Myers Squibb
PII-096 - DEVELOPMENT OF A PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL TO PREDICT PHARMACOKINETICS AND DRUG-DRUG INTERACTIONS FOR REPOTRECTINIB
Sheena Sharma
Favorite
Sheikhy, Morasa

Biogen
LB-011 - BIIB091, A NONCOVALENT BRUTON'S TYROSINE KINASE (BTK) INHIBITOR IN DEVELOPMENT FOR TREATMENT OF MULTILE SCLEROSIS (MS): MASS BALANCE, ELIMINATION ROUTE, AND METABOLISM IN HEALTHY MALE PARTICIPANTS.
Morasa Sheikhy
Favorite
Shenkoya, Babajide

University of Maryland Baltimore
PT-021 - IS ENOXAPARIN DOSING ADEQUATE FOR THROMBOPROPHYLAXIS IN BURN PATIENTS? INSIGHTS FROM REAL-WORLD DATA USING PHARMACOMETRIC MODELING.
Babajide Shenkoya
Favorite
PWI-004 - IS ENOXAPARIN DOSING ADEQUATE FOR THROMBOPROPHYLAXIS IN BURN PATIENTS? INSIGHTS FROM REAL-WORLD DATA USING PHARMACOMETRIC MODELING.
Babajide Shenkoya
Favorite
Singh, Amarinder

The University of Tennesse Heath Sciences
PT-013 - USING MODEL-BASED SIMULATIONS TO ALIGN MOUSE ANTIBIOTIC EXPOSURE WITH HUMAN CLINICAL EFFICACY FOR EXPLORATION OF COMBINATION THERAPY IN TUBERCULOSIS
Amarinder Singh
Favorite
Singh, Rajendra

Teva Branded Pharmaceutical Products R&D, Inc.
PI-083 - POPULATION PHARMACOKINETIC ANALYSIS OF DUVAKITUG (TEV-48574) IN HEALTHY PARTICIPANTS AND PATIENTS WITH ASTHMA.
Rajendra Singh
Favorite
Sinha, Jaydeep

Daiichi Sankyo, Inc.
PII-070 - FIRST-IN-PEDIATRIC DOSE SELECTION OF PATRITUMAB DERUXTECAN USING MODELING AND SIMULATION
Jaydeep Sinha
Favorite
Sinha, Vikash

Janssen Research & Development, LLC, Spring House, PA, USA
PI-016 - SELTOREXANT DOES NOT PROLONG THE QT INTERVAL: A PLACEBO- AND POSITIVE-CONTROLLED, SINGLE DOSE PHASE 1 STUDY IN HEALTHY ADULTS
Vikash Sinha
Favorite
Smith, Tayler

Indiana University School of Medicine
PII-041 - A CASE OF HEPATOTOXICITY DURING COMBINATION AXITINIB AND PEMBROLIZUMAB THERAPY IN A CYP3A4 AND CYP3A5 DUAL POOR METABOLIZER
Tayler Smith
Favorite
Song, Daihyun

Department of Pharmacology, University of Minnesota
PII-092 - THE EFFECT OF POLYDRUG USE AND FENTANYL VACCINE ON THE PHARMACOKINETICS OF FENTANYL
Daihyun Song
Favorite
Springer, Ashley

Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine
PII-116 - DEVELOPMENT OF CHARACTERIZATION OF A TRANSDERMAL DRUG DELIVERY SYSTEM FOR ALZHEIMER'S DRUGS.
Ashley Springer
Favorite
PT-024 - EVALUATION OF PRESCRIBER BEHAVIOR IN RESPONSE TO CYP2C19-CLOPIDOGREL BEST PRACTICE ALERTS.
Ashley Springer
Favorite
Stephens, Taylor

University of Kansas Medical Center
PT-026 - EXPLORING THE RELATIONSHIP BETWEEN ANTIDEPRESSANT TREATMENT, NEUROCHEMICALS IN THE BRAIN AND ANXIETY/DEPRESSION SYMPTOMS IN YOUTH
Taylor Stephens
Favorite
Stocco, Gabriele

University of Trieste / Institute for Maternal and Child Health IRCCS Burlo Garofolo
PII-005 - ITPA ACTIVITY TO PREDICT REMISSION WITH METHOTREXATE IN JUVENILE IDIOPATHIC ARTHRITIS
Gabriele Stocco
Favorite
Sun, Steven

Pfizer Inc.
PI-027 - ASSESSING BASELINE AND LONGITUDINAL CIRCULATING TUMOR DNA WITH PROGRESSION FREE SURVIVAL (PFS) IN BRAF V600E MUTANT (BRAFM) METASTATIC COLORECTAL CANCER (MCRC).
Steven Sun
Favorite
Sun, Yuchen

University of Michigan
PII-077 - PHARMACODYNAMIC MODEL OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN PATIENTS WITH BREAST CANCER RECEIVING PACLITAXEL
Yuchen Sun
Favorite
T
Tait, Jessica

Monash University
PI-103 - UTILISING PHYSIOLOGICAL LYMPH FLOWS TO ENHANCE A MINIMAL PHYSIOLOGICALLY BASED PHARMACOKINETIC AND QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL FOR BIODISTRIBUTION OF MRNA ENCAPSULATED IN LIPID NANOPARTICLES WITH LIPID 5 IN RATS
Jessica Tait
Favorite
Tammara, Brinda

Johnson and Johnson
PII-078 - PHARMACOKINETIC BRIDGING OF JNJ-77242113 ORAL SOLUTION AND TABLET FORMULATIONS.
Brinda Tammara
Favorite
Tang, Alice

Genentech, Inc
PII-011 - CHARACTERIZING QTC PROLONGATION RISK FROM CONCOMITANT MEDICATIONS IN PATIENTS WITH BREAST CANCER AMONG PHARMETRICS PLUS.
Alice Tang
Favorite
Tan, Shawn Pei Feng

The University of Manchester
PT-016 - DEVELOPMENT OF ADEFOVIR PBPK MODEL TO SUPPORT PROSPECTIVE EVALUATION OF BIOMARKER-INFORMED OAT1 INHIBITION AND EFFECT OF RENAL IMPAIRMENT
Shawn Pei Feng Tan
Favorite
PWII-002 - DEVELOPMENT OF ADEFOVIR PBPK MODEL TO SUPPORT PROSPECTIVE EVALUATION OF BIOMARKER-INFORMED OAT1 INHIBITION AND EFFECT OF RENAL IMPAIRMENT
Shawn Pei Feng Tan
Favorite
Tantawy, Marwa

University of Florida
PI-043 - ATORVASTATIN AS A CARDIOPROTECTIVE AGENT AGAINST CARFILZOMIB-INDUCED CARDIOTOXICITY IN HUMAN INDUCED PLURIPOTENT STEM CELL-DERIVED CARDIOMYOCYTES.
Marwa Tantawy
Favorite
PI-047 - GENOME-WIDE ASSOCIATION STUDY IDENTIFIES GENETIC VARIANTS ASSOCIATED WITH CARDIOVASCULAR ADVERSE EVENTS IN BREAST CANCER PATIENTS TREATED WITH AROMATASE INHIBITORS: RESULTS FROM THE ALL OF US.
Marwa Tantawy
Favorite
Tan, Zhengqi

Pumas-AI, inc.
PI-032 - MODEL INFORMED DOSE OPTIMIZATION OF BOTENSILIMAB ALONE AND IN COMBINATION WITH BALSTILIMAB IN PATIENTS WITH SOLID TUMORS
Zhengqi Tan
Favorite
Taylor, Zachary

Cincinnati Children's Hospital Medical Center
PII-064 - DRUG-DRUG INTERACTION MODEL DESCRIBES HIGH-DOSE METHOTREXATE PHARMACOKINETICS AFTER GLUCARPIDASE RESCUE
Zachary Taylor
Favorite
Thakur, Aarzoo

Department of Pharmaceutical Sciences, Washington State University
PII-007 - PYRIDOXIC ACID AS ENDOGENOUS BIOMARKER OF RENAL ORGANIC ANION TRANSPORTER ACTIVITY: POPULATION VARIABILITY AND MECHANISTIC MODELING TO PREDICT DRUG-DRUG INTERACTIONS
Aarzoo Thakur
Favorite
PT-001 - UTILITY OF A PANEL OF ENDOGENOUS BIOMARKERS TO PREDICT DRUG-DRUG INTERACTIONS AND INTERINDIVIDUAL VARIABILITY INVOLVING ORGANIC ANION TRANSPORTERS 1 AND 3 ACTIVITY.
Aarzoo Thakur
Favorite
PWII-001 - UTILITY OF A PANEL OF ENDOGENOUS BIOMARKERS TO PREDICT DRUG-DRUG INTERACTIONS AND INTERINDIVIDUAL VARIABILITY INVOLVING ORGANIC ANION TRANSPORTERS 1 AND 3 ACTIVITY.
Aarzoo Thakur
Favorite
Thomas, Cameron

University of Florida
OAI-003 - REAL-WORLD CLINICAL OUTCOMES BY P2Y12 INHIBITOR THERAPY AND GENOTYPE IN BLACK VERSUS NON-BLACK PATIENTS FOLLOWING PCI.
Cameron Thomas
Favorite
PT-008 - REAL-WORLD CLINICAL OUTCOMES BY P2Y12 INHIBITOR THERAPY AND GENOTYPE IN BLACK VERSUS NON-BLACK PATIENTS FOLLOWING PCI.
Cameron Thomas
Favorite
Thompson, Corbin

Amgen, Inc.
PI-035 - PHARMACOKINETICS OF TARLATAMAB, A DELTA LIKE LIGAND-3 (DLL3) TARGETED HALF-LIFE EXTENDED BISPECIFIC T-CELL ENGAGER (BITE) IMMUNOTHERAPY IN PATIENTS WITH PREVIOUSLY TREATED NEUROENDROCRINE PROSTATE CANCER (NEPC)
Corbin Thompson
Favorite
Tumberger, John

Children's Mercy Kansas City
PT-017 - FLUOXETINE RESPONSE ASSOCIATED WITH ENANTIOMER ABUNDANCE IN ADOLESCENTS.
John Tumberger
Favorite
U
Ujihira, Yuki

The University of Manchester
PI-005 - HOLISTIC CREDIBILITY ASSESSMENT OF PBPK MODELS FOR TRANSPORTER ENDOGENOUS BIOMARKERS: THE CASE OF COPROPORPHYRIN-I .
Yuki Ujihira
Favorite
V
Vuu, Irene

Amgen Inc.
PII-080 - PHARMACOKINETICS OF A FULLY HUMAN BISPECIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) AND CLUSTER OF DIFFERENTIATION (CD3) BINDING MONOCLONAL ANTIBODY (AMG 340) IN SUBJECTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER
Irene Vuu
Favorite
W
Wagner, John

Koneksa Health
PII-003 - COMPLIANCE, USABILITY, RELIABILITY, AND CONSTRUCT VALIDITY OF SELF-ADMINISTERED DIGITAL MEASURES DERIVED FROM MDS-UPDRS PARTS 2 AND 3 IN AN OBSERVATIONAL STUDY TO EVALUATE PARKINSON'S DISEASE (PD) PROGRESSION: INTERIM ANALYSIS.
John Wagner
Favorite
Walton, Mollie

Children's Mercy Hospital
PII-120 - MARFAN: MAXIMIZING ATENOLOL RESPONSE THROUGH FUNCTIONAL ASSESSMENT INVESITGATIONS AMONGST CONNECTIVE TISSUE DISORDERS
Mollie Walton
Favorite
Wang, Hechuan

Pfizer, Inc.
PII-039 - THE EFFECT OF CARBAMAZEPINE ON THE PHARMACOKINETICS (PK) OF VEPDEGESTRANT, A PROTEOLYSIS TARGETING CHIMERA (PROTAC) ESTROGEN RECEPTOR (ER) DEGRADER IN HEALTHY ADULTS.
Hechuan Wang
Favorite
Wang, Lei

The Ohio State University
PI-115 - THE MATERNAL AND PEDIATRIC PRECISION IN THERAPEUTIC (MPRINT) KNOWLEDGEBASE PORTAL: A POWERFUL INFRASTRUCTURE FOR MATERNAL AND PEDIATRIC PRECISION THERAPEUTICS RESEARCH
Lei Wang
Favorite
wang, lujing

Bristol Myers Squibb
PII-104 - UTILIZING A MINIMAL PBPK (MPBPK) MODEL TO PREDICT INTRA-TUMORAL CONCENTRATIONS OF MONOCLONAL ANTIBODIES.
lujing wang
Favorite
Wang, Meijie

Mayo Clinic
PI-044 - DISRUPTING THE PD-L1 AND PDS5B INTERACTION BY COMPOUNDS: A PROMISING THERAPEUTIC STRATEGY FOR TRIPLE-NEGATIVE BREAST CANCER.
Meijie Wang
Favorite
Wang, Shirley

University of Waterloo
PT-015 - ADVANCEMENTS IN PEDIATRIC PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING OF DRUGS IN LACTATION FOR GUIDING NEONATAL EXPOSURE RISK ASSESSMENT
Shirley Wang
Favorite
PWI-003 - ADVANCEMENTS IN PEDIATRIC PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING OF DRUGS IN LACTATION FOR GUIDING NEONATAL EXPOSURE RISK ASSESSMENT
Shirley Wang
Favorite
wang, xue

Mayo Clinic
PII-045 - DNA METHYLTRANSFERASE INHIBITORS REDUCE TRIPLE NEGATIVE BREAST CANCER CELL GROWTH THROUGH ENHANCED IMMUNE RESPONSE BY DOWNREGULATION OF ZNF101
xue wang
Favorite
Wickramasinghe, Charuka

Karmanos Cancer Institute
PI-085 - POPULATION PHARMACOKINETIC MODEL OF TOTAL AND UNBOUND PAMIPARIB, A PARP INHIBITOR, IN GLIOBLASTOMA PATIENTS
Charuka Wickramasinghe
Favorite
PII-103 - SPATIALCNS-PBPK: AN R/SHINY WEB-BASED PLATFORM FOR PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING OF SPATIAL PHARMACOKINETICS IN THE HUMAN CENTRAL NERVOUS SYSTEM AND BRAIN TUMORS
Charuka Wickramasinghe
Favorite
Wilbaux, Melanie

Pumas-AI, inc.
PII-074 - MODEL INFORMED DOSE OPTIMIZATION OF BALSTILIMAB TO SUPPORT FIXED DOSING ALONE AND IN COMBINATION WITH BOTENSILIMAB IN PATIENTS WITH SOLID TUMORS.
Melanie Wilbaux
Favorite
Williams, Jonathan

Longboard Pharmaceuticals
PII-073 - MASS BALANCE, METABOLISM, AND EXCRETION OF [14C] BEXICASERIN IN A SINGLE DOSE RADIOLABEL STUDY IN HEALTHY ADULT MALES.
Jonathan Williams
Favorite
Wu, Fang

U.S. Food and Drug Administration
PII-099 - PBPK MODELING TO PREDICT THE EFFECT OF GASTRIC PH ON BIOEQUIVALENCE OF PALBOCICLIB TABLETS
Fang Wu
Favorite
Wu, Liviawati

Jazz Pharmaceuticals
PI-074 - MODEL-BASED DRUG DEVELOPMENT CONSIDERATIONS: ZANIDATAMAB IN PATIENTS WITH HER2 EXPRESSING BILIARY TRACT CANCER (BTC)
Liviawati Wu
Favorite
Wu, Yanting

Division of Clinical Pharmacology, Indiana University School of Medicine
PII-115 - A SIMPLE AND SENSITIVE ULTRA-HIGH PERFORMANCE LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY (UHPLC-MS/MS) ASSAY TO QUANTIFY TIZANIDINE AND ITS METABOLITES IN HUMAN PLASMA
Yanting Wu
Favorite
PII-118 - EFAVIRENZ ALTERS THE DISPOSITION AND PHARMACODYNAMICS OF TIZANIDINE IN HEALTHY VOLUNTEERS
Yanting Wu
Favorite
X
Xu, Christine

Sanofi
PI-011 - ABSORPTION OF ELIGLUSTAT VIA THE BUCCAL CAVITY FOLLOWING ORAL ADMINISTRATION OF ELIGLUSTAT SOLUTION IN HEALTHY ADULT PARTICIPANTS.
Christine Xu
Favorite
PII-055 - A RANDOMIZED, THREE-PERIOD, CROSSOVER STUDY OF SINGLE AND REPEATED DOSES OF ELIGLUSTAT IN HEALTHY PARTICIPANTS, CYP2D6 EXTENSIVE AND POOR METABOLIZERS
Christine Xu
Favorite
Y
Yahya, Nawal

Mayo Clinic
LB-015 - POPULATION PHARMACOKINETICS OF THE PARP INHIBITOR VELIPARIB IN PATIENTS WITH ADVANCED CANCER.
Nawal Yahya
Favorite
Yang, Derek

Pfizer Inc.
PII-082 - POPULATION EXPOSURE-RESPONSE ANALYSIS OF INOTUZUMAB OZOGAMICIN EFFICACY AND SAFETY IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA.
Derek Yang
Favorite
PII-083 - POPULATION PHARMACOKINETIC (POPPK) MODELING OF ENCORAFENIB (ENCO) IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH BRAF V600-MUTANT SOLID TUMORS IN PHASE 1, 2, AND 3 STUDIES: A SEMIMECHANISTIC AUTOINDUCTION MODEL.
Derek Yang
Favorite
Yang, Eunsol

University of California, San Francisco
PI-020 - PREDICTING OPTIMAL PATIENT-CENTRIC TREATMENT DURATION FOR LEVOFLOXACIN-CONTAINING TUBERCULOSIS REGIMEN: AN INTEGRATED APPROACH OF A MODEL-BASED STRATIFICATION TOOL WITH SITE-OF-DISEASE PHARMACOLOGY KNOWLEDGE
Eunsol Yang
Favorite
PII-019 - POPULATION PHARMACOKINETICS OF DELAMANID AND ITS METABOLITE DM-6705 IN MULTIDRUG-RESISTANT TUBERCULOSIS PATIENTS RECEIVING NOVEL SHORT-COURSE ORAL REGIMENS IN THE ENDTB AND ENDTB-Q TRIALS
Eunsol Yang
Favorite
Yang, HyeokJun

jeju National University
PII-126 - DEVELOPMENT OF A SKIN DRYNESS PREDICTION MODEL BASED ON FACIAL IMAGES USING DEEP LEARNING: A PROSPECTIVE COHORT STUDY.
HyeokJun Yang
Favorite
Yang, Xinning

US Food and Drug Administration
LB-022 - CAN THE POTENTIAL OF A DRUG TO INHIBIT URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE (UGT) ENZYMES BE PREDICTED? INSIGHTS FROM A RETROSPECTIVE ANALYSIS.
Xinning Yang
Favorite
Yoon, Michael

University of California, San Francisco
PT-025 - EVALUATION OF PYRAZINAMIDE PHARMACOKINETICS IN ADOLESCENTS AND ADULTS TO INFORM TUBERCULOSIS DOSING RECOMMENDATIONS.
Michael Yoon
Favorite
Yoshihara, Tatsuya

SOUSEIKAI Fukuoka Mirai Hospital Clinical Research Center
PI-050 - INFLUENCE OF ALDH2 RS671 POLYMORPHISM ON ANTIBODY TITER AFTER INFLUENZA VACCINATION: A PROSPECTIVE OBSERVATIONAL STUDY
Tatsuya Yoshihara
Favorite
Yu, Amanda

UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences
PI-057 - AN INVESTIGATION INTO THE DOSE-DEPENDENT FOOD-EFFECT FOR DRUGS.
Amanda Yu
Favorite
Yu, Sijia

Department of Pharmaceutics and Center of Excellence for Pharmaceutical Translational Research and Education, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey
PT-028 - MITIGATING CARDIOTOXICITY OF TRASTUZUMAB AND DOXORUBICIN COMBINATION THERAPY WITH AN INTEGRATED TRANSLATIONAL AND QUANTITATIVE SYSTEMS TOXICOLOGY AND PBPK/PD MODELING APPROACH
Sijia Yu
Favorite
PWII-004 - MITIGATING CARDIOTOXICITY OF TRASTUZUMAB AND DOXORUBICIN COMBINATION THERAPY WITH AN INTEGRATED TRANSLATIONAL AND QUANTITATIVE SYSTEMS TOXICOLOGY AND PBPK/PD MODELING APPROACH
Sijia Yu
Favorite
YU, XIAOYI

MSD R&D (China) Co., Ltd.
PI-070 - IMPACT OF EAST ASIAN ETHNICITY ON PHARMACOKINETICS OF SOTATERCEPT
XIAOYI YU
Favorite
Z
ZHANG, Lin

The Chinese University of Hong Kong
PI-073 - MECHANISM-BASED PHARMACOKINETIC-PHARMACODYNAMIC MODELING OF ERYTHROFERRONE: OPTIMIZING RECOMBINANT HUMAN ERYTHROPOIETIN DOSING IN CKD-INDUCED ANEMIA
Lin ZHANG
Favorite
Zhang, Victoria

Tufts University School of Medicine
PI-122 - WHAT CAN WE LEARN FROM TRENDS IN PATIENT RECRUITMENT ADVERTISING IN THE PAST 20 YEARS?
Victoria Zhang
Favorite
Zhao, Chen

Nanjing Medical University
PI-123 - A MECHANISTIC QUANTITATIVE SYSTEMS PHARMACOLOGY FRAMEWORK FOR MODEL-INFORMED TRANSLATIONAL ASSESSMENT OF MESENCHYMAL STEM CELL THERAPY IN LUPUS NEPHRITIS
Chen Zhao
Favorite
Zhao, Sherry

Bristol Myers Squibb
PII-058 - APPROACHES TO HANDLING MISSING DOSING IN POPULATION PHARMACOKINETIC MODELING DUE TO NON-ADHERENCE
Sherry Zhao
Favorite
Zhong, Rui

University of North Carolina at Chapel Hill / Bristol Myers Squibb
PII-085 - POPULATION PHARMACOKINETIC AND EXPOSURE-RESPONSE ANALYSIS OF ABATACEPT IN COVID-19 PATIENTS
Rui Zhong
Favorite
Zhou, Jian

Bristol Myers Squibb
PI-086 - POPULATION PHARMACOKINETIC OF BMS-986365, A DUAL ANDROGEN RECEPTOR (AR) LIGAND-DIRECTED DEGRADER AND ANTAGONIST, IN PATIENTS WITH PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Jian Zhou
Favorite
Zhou, Xujia

University of California San Francisco
PII-060 - CHALLENGES IN PREDICTING PEDIATRIC DRUG EXPOSURE WITH ALLOMETRIC SCALING: IMPLICATIONS FOR OPTIMIZING PEDIATRIC TRIAL DESIGNS
Xujia Zhou
Favorite
Zimmerman, Eric

Pfizer Inc
PI-053 - A PHASE 1 MICROTRACER STUDY EVALUATING THE MASS BALANCE, EXCRETION, AND PHARMACOKINETICS OF [14C]-GBT021601, AN ORAL SICKLE HEMOGLOBIN POLYMERIZATION INHIBITOR, IN HEALTHY PARTICIPANTS.
Eric Zimmerman
Favorite
ZUNINO, Chiara

Phinc Development, Massy France
PI-102 - PREDICTION OF A CLAUDIN 18.2 TARGETED ANTIBODY DRUG CONJUGATE (ADC) PHARMACOKINETICS IN CANCER PATIENTS USING PBPK MODELING AND SIMULATION
Chiara ZUNINO
Favorite